Erik Harris
CIK: 0001780113
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Apr 16, 2026RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct28.9K shares- - Mar 2, 2026RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Direct10.5K shares at avg. $22.80$240K - Mar 1, 2026RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct11.6K shares- - Nov 19, 2025RZLT
Rezolute, Inc.
Award(A)Direct21K shares- - Mar 25, 2025RZLT
Rezolute, Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
60K shares- - Mar 3, 2025RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Direct15.1K shares at avg. $42.10$636K - Mar 1, 2025RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct16.8K shares- - Mar 1, 2025RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct18.4K shares- - Oct 3, 2024INZY
Inozyme Pharma, Inc.
Award(A)DirectStock Option (right to buy)
56K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 16, 2026 |  RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 28,895 | - | $0 | Direct |
| Mar 2, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 10,539 | $22.80 | $240,289 | Direct |
| Mar 1, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 11,643 | - | $0 | Direct |
| Nov 19, 2025 |  RZLT Rezolute, Inc. | Award(A) | 21,000 | - | - | Direct |
| Mar 25, 2025 | RZLT Rezolute, Inc. | Award(A) Director Stock Option (Right to Buy) | 60,000 | - | - | Direct |
| Mar 3, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 15,103 | $42.10 | $635,836 | Direct |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 16,813 | - | - | Direct |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 18,443 | - | - | Direct |
| Oct 3, 2024 |  INZY Inozyme Pharma, Inc. | Award(A) Stock Option (right to buy) | 56,000 | - | - | Direct |
1-9 of 9 transactions
About Harris Erik
Harris Erik (SEC CIK 0001780113) files insider reports with the SEC as EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc. (RARE), Director of Rezolute, Inc. (RZLT) and Director of Inozyme Pharma, Inc. (INZY).
Signal8 holds 8 ownership filings by Harris Erik (2 Form 3, 6 Form 4), filed between Oct 7, 2024 and Apr 20, 2026. Those filings report 9 transactions, from Oct 3, 2024 to Apr 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Harris Erik's filings is in NOVATO, CA.
Recent filings by Harris Erik
- Apr 16, 2026: Grant or award of RARE shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of RARE shares (Form 4, code S).
- Mar 1, 2026: Grant or award of RARE shares (Form 4, code A).
- Nov 19, 2025: Grant or award of RZLT shares (Form 4, code A).
- Mar 25, 2025: Grant or award of RZLT derivative securities (Form 4, code A).
Other insiders filing for Ultragenyx Pharmaceutical Inc. (RARE)
- Horn Howard, Chief Financial Officer
- Huizenga Theodore Alan, SVP, Chief Accounting Officer
- Parschauer Karah Herdman, EVP and Chief Legal Officer
- Sanders Corazon (Corsee) D., Director
- Fust Matthew K, Director
- SULIMAN SHEHNAAZ, Director